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Abstract
Background
Ferritin constitutes a sensitive iron-storage index and multi-functional protein. Evidence on
its association with mortality in general population is scarce and conflicting. We investigated
the sex-specific associations of ferritin levels with all-cause and cardiovascular mortality in a
population-based cohort.
Methods
Data came from the English Longitudinal Study of Ageing and the national mortality registry.
The sample comprised 5,471 participants aged52 years. Blood concentration of ferritin
was measured at baseline in 2004–05. Sex-specific Cox proportional hazards models were
estimated with adjustment for age, major chronic diseases, marital status, educational
attainment, total net household wealth, anemia, inflammatory markers, body mass index,
smoking, and physical activity. Stratified analyses by chronic disease status were also
performed.
Results
We categorized ferritin in sex-specific quartiles. In men, we used, the following categoriza-
tion: lowest (2-69ng/ml), second lowest (70-118ng/ml), second highest (reference category)
(119-193ng/ml) and highest (194-598ng/ml) ferritin quartiles. In women, ferritin was catego-
rized as follows: lowest (2-44ng/ml), second lowest (45-73ng/ml), second highest (reference
category) (74-115ng/ml) and highest (116-341ng/ml) ferritin quartiles. 841 deaths of which
262 cardiovascular disease-related were recorded over a mean follow-up time of 7.7 years.
Risk for all-cause mortality was found increased in men with hyperferritinemia (194-598ng/
ml) and no history of major chronic diseases compared with the reference group [fully-
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adjusted HR: 1.49 (95%CI 1.03–2.16)]. Among women, those in the lowest ferritin quartile
(2-44ng/ml) had increased risk for all-cause mortality [fully-adjusted HR: 1.59 (95%CI 1.18–
2.13)] compared with the reference group after adjustment for all covariates. Regarding car-
diovascular mortality, we observed a positive association with ferritin levels in men, which
was blunted after adjustment for inflammatory markers and lifestyle parameters. Men with
no major chronic diseases who were in the highest ferritin quartile had a significantly
increased risk of cardiovascular mortality. No association between ferritin levels and cardio-
vascular mortality was detected in women.
Conclusion
Circulating ferritin levels showed sex-specific prognostic patterns. High ferritin levels in men
with no major chronic disease and low ferritin levels in all women were associated with
increased all-cause mortality after adjusting for covariates. High ferritin levels in men with no
major chronic diseases were also independently associated with an increased risk of cardio-
vascular mortality. Future research is needed to clarify the prognostic role of ferritin.
Introduction
Ferritin is an iron-containing protein and its measurement in serum may reliably reflect the
human iron storage homeostasis which is essential in fundamental metabolic processes in liv-
ing organisms [1]. Excessively elevated ferritin concentrations (hyper-ferritinemia) may indi-
cate iron overload, which is toxic for several organs (e.g. myocardium, liver etc) and has been
associated with increased morbidity and mortality [2]. On the other hand, low ferritin levels
(hypo-ferritinemia) mirrors iron depletion, which is also related to higher morbidity and mor-
tality [3,4].
Ferritin, beyond its function as an iron-storage marker, is a multi-functional protein with
possible roles not only in iron delivery, but in proliferation, angiogenesis, and immunosup-
pression [5]. It is also an acute-phase protein, whose synthesis is driven by cytokines and its
levels increase in inflammatory conditions [6]. There are conflicting results highlighting the
pluripotency of ferritin as a biomarker in a wide variety of diseases. Previous observational
studies have found a positive relationship between high serum ferritin levels and the develop-
ment of chronic diseases, like coronary artery disease (CAD) [7], cancer [8], and their adverse
progression [9]. Other studies failed to find an association between high ferritin levels and
chronic diseases [10] or found inverse relationships where low ferritin levels correlated to the
development of CAD [11] and cancer [12]. It remains unknown whether ferritin is a bystander
or a causative factor in the development of numerous chronic diseases. Moreover, a clear cut-
off value of ferritin related to adverse events is still elusive. Despite the potential importance of
ferritin as a prognostic biomarker, only a few observational studies have investigated its associ-
ation with mortality in community samples [13–15]. Those studies reported either a weak
association between low ferritin levels and poor prognosis, or failed to demonstrate any associ-
ation between ferritin levels and survival.
Scarce data support sex differences in ferritin associations with other diseases [16]. Although
most women in reproductive age appear with negative iron balance due to poor diet and men-
strual blood loss, the underlying mechanisms of gender differences is ferritin level are not
entirely attributed to the said negative balance and presumably other unknown mechanisms
Association between ferritin and mortality
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remain [17]. Our initial hypothesis was that there are sex-specific associations between serum
ferritin levels and the risk of all-cause and cardiovascular mortality. Thereby we aimed to
explore those sex-differences in a national sample of older community-dwellers. We further
examined the impact of covariates, including anemia and inflammation, on the above associa-
tions and whether the observed associations held in a subgroup free of major chronic diseases
at baseline.
Material and methods
Study population
The English Longitudinal Study of Ageing (ELSA) is an ongoing biennial survey of commu-
nity-d.welling people aged 50 years and older in England, and was designed to be nationally
representative. The ELSA sample was drawn from households that had participated in the
Health Survey for England (HSE) in 1998, 1999, and 2001 [18]. At wave 1, in 2002–2003, the
ELSA sample comprised 11,391 core participants. The first follow-up interview and first health
examination took place at wave 2 in 2004–2005, at the respondents’ home. The health exami-
nation took place after the interview and involved the collection of blood samples and the
measurement of clinical and other health data including anthropometric data. A detailed
description of the study can be found at: http://www.elsa-project.ac.uk/. Our study complied
with the Declaration of Helsinki, and the locally appointed ethics committee approved the
research protocol. An informed consent was obtained from the participants.
For the needs of our analyses, we used interview and health examination data from ELSA
wave 2 (2004–2005). Of the 8,780 individuals who participated in wave 2, 6,652 agreed to par-
ticipate in the health examination, consented and were eventually eligible to give blood sam-
ples. Individuals fulfilling any of the following criteria were not eligible for blood sampling:
clotting or bleeding disorders, anti-coagulant medication (such as warfarin or acenocoumarol)
at the time of interview, history of fits or convulsions, current or recent iron replacement ther-
apy. Of the 6,652 consenting participants, we had valid ferritin measurement for 5,906 partici-
pants. The analytical sample comprised 5,471 individuals aged 50 years and older after the
exclusion of 373 individuals with missing covariate data or who did not consent to data
linkage to the national register of deaths. We also excluded 62 individuals with excessively
high ferritin values (i.e. those in the top 1% of the ferritin distribution—30 men with ferritin
levels 599ng/ml and 32 women with ferritin levels 342ng/ml), as it was likely that they
presented with overt pathology.
Ferritin measurement
After blood collection, samples were dispatched to the Royal Victory Infirmary in Newcastle-
upon-Tyne, UK for processing and analysis. Blood samples received by the laboratory later
than five days after collection were not used. The concentration of ferritin was measured using
Advia Centaur ferritin immunoassay by Bayer. More information on the measurement of fer-
ritin and other blood analytes used in our analysis can be obtained from the HSE 2005 techni-
cal report (http://bit.ly/1QvuNwW); both ELSA and the HSE used the same infrastructure and
protocols to analyse the blood samples.
There are no established ferritin cut-points to define iron depletion or overload, and there-
fore, we categorized ferritin into sex-specific quartiles. The distributions of quartiles were as
follows: 1) In men: lowest concentration quartile: 2 to 69ng/ml, second lowest concentration
quartile: 70 to 118ng/ml, second highest concentration quartile: 119 to 193ng/ml, and highest
concentration quartile: 194 to 598ng/ml. 2) In women: lowest concentration quartile: 2 to
44ng/ml, second lowest concentration quartile: 45 to 73ng/ml, second highest concentration
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quartile: 74 to 115ng/ml, and highest concentration quartile: 116 to 341ng/ml. For statistical
analysis purposes, we selected the second highest quartile as the reference category since it
showed the lowest relative all-cause and cardiovascular mortality in both men and women.
Outcome variable
Death registrations up to February 2013 were obtained from the Office for National Statistics
for participants consenting to data linkage. Underlying cause of death was classified according
to ICD10. Deaths with ICD10 codes I00 to I99 were classified as cardiovascular deaths.
Covariates
Age, marital status (married versus not), major self-reported doctor diagnosed diseases i.e.
heart disease, stroke, cancer, chronic lung disease, and diabetes mellitus, educational attain-
ment (measured using three levels ranging from no qualifications to A-levels or higher), and
total net household wealth (divided into tertiles) were considered as potential confounders.
Baseline body mass index (<25 kg/m2, 25 to<30 kg/m2, and30 kg/m2), self-reported smok-
ing (current, former, or never smoker), and physical activity (categorized in four categories
ranging from no physical activity to vigorous physical activity at least once a week) were
included as covariates. Due to the small number of individuals in the underweight category
(i.e. BMI<18.5) (n = 28 women and n = 15 men) we merged this category with the normal
weight. Anemia was measured using hemoglobin according to the World Health Organization
criteria (WHO): <13g/dL in men and<12g/dL in women [19]. High sensitivity C-reactive
protein (hsCRP) and fibrinogen were used as markers of inflammation; hsCRP was log trans-
formed because of its markedly skewed distribution. Marital status, socioeconomic position
markers such as education and wealth are major determinants of human health and could well
be confounding the observed associations.
Statistical analyses
Multivariable sex-specific Cox proportional hazard regression models were estimated to inves-
tigate the associations between ferritin quartiles, cardiovascular and all-cause mortality. We
confirmed that the proportionality assumption held using the Schoenfeld residuals test and
log-log survival plots.
We sequentially adjusted our models for age (Model 1), then additionally for marital status,
educational attainment, total net household wealth, and baseline self-reported doctor diag-
nosed diseases i.e. heart disease, stroke, cancer, chronic lung disease, and diabetes mellitus
(Model 2), anemia (Model 3), hsCRP and fibrinogen (Model 4), and finally body mass index,
smoking, and physical activity (Model 5). The adjustments for anemia and inflammation
aimed to explore the role of these conditions in the observed associations.
To investigate whether ferritin could be a potential biomarker of future adverse outcomes
and mortality amongst older individuals without major chronic diseases at baseline, we esti-
mated models that excluded individuals with the following self-reported doctor-diagnosed
chronic diseases: heart disease, stroke, cancer, chronic lung disease, and diabetes. This exclu-
sion might also reduce the possibility of reverse causation i.e. low or high levels of ferritin
being a product of baseline health conditions and chronological proximity to death. To further
address this issue, in the supplementary analyses, we also excluded deaths that occurred within
the first 24 months after the baseline measurements in 2004–2005. In a final step, we excluded
individuals with anemia or high levels of hsCRP (i.e. >3mg/L) to determine whether ferritin
predicted mortality among people without anemia or chronic low-grade inflammation. All
analyses were performed using Stata 13, with a significance threshold of less than 0.05.
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Results
Significant differences in age, socioeconomic position, physical activity, body mass index, ane-
mia, and hsCRP levels by ferritin quartiles were observed in both men and women (Table 1).
In the whole population study, serum ferritin concentration was higher in men than in
women, with a median of 119ng/ml (IQR: 69-193ng/ml), and 74ng/ml (IQR 44-115ng/ml),
respectively. The sensitivity analysis performed was essential to rule out the random effect of
baseline clinical conditions, leading to early death (S1 Table).
Over a mean follow-up time of 7.7 years, 841 deaths, of which 262 of cardiovascular origin,
were recorded in the whole cohort. There was no association between ferritin levels and all-
cause mortality in men. However, in the subgroup of men without baseline major chronic dis-
ease, high levels of ferritin (i.e. 194-598ng/ml) were associated with an increased risk of mor-
tality independent of all covariates. In women, those with low ferritin levels (2-44ng/ml) were
at increased risk of all-cause mortality compared to women in the reference category (second
highest ferritin quartile: 74-115ng/ml) irrespective of adjustment for covariates. This associa-
tion persisted after the exclusion of major baseline chronic diseases (Table 2).
In men, there was a positive association between highest ferritin quartiles and the risk of
cardiovascular mortality after adjustment for age, chronic diseases and anemia. Adjustment
for additional covariates (lifestyle, inflammation) attenuated this association and in this case
men with ferritin levels belonging to the second lowest quartile showed significantly increased
cardiovascular mortality than those in the reference category (i.e. second highest ferritin quar-
tile: 119-193ng/ml) (Table 2). Among men without major baseline chronic diseases, those with
the highest ferritin levels had considerably increased risk of cardiovascular mortality compared
to reference group after full adjustment for covariates (models 3, 4 and 5). Women with low
ferritin levels (2-44ng/ml) were at increased risk of cardiovascular mortality, although this
association did not reach statistical significance.
Discussion
The present analysis was based on a national sample of community-dwelling people aged 50
years or older and used one of the largest known samples (ELSA) to explore the sex-specific
prognostic role of ferritin. Healthy men with hyperferritenemia (194-598ng/ml) were at a sig-
nificantly increased risk of all-cause and cardiovascular mortality compared to the reference
category. In the entire male population, the increased risk for cardiovascular mortality hyper-
ferritinemia was attenuated after adjustment for inflammatory and lifestyle covariates. More-
over, our findings indicated significantly higher hazard for all-cause mortality amongst
women with low ferritin serum levels (2-44ng/ml), which persisted after adjustment for
covariates.
A growing body of evidence has suggested that excessive values of ferritin, either low or
high, may be predictive of increased mortality in patients with hematological [20], kidney,
metabolic, cardiovascular [21], neoplasmatic [22], and other diseases. Regarding all-cause
mortality in men, we found a positive association with high ferritin quartiles, but only in the
subgroup without any baseline major chronic disease. Because of this variation by chronic dis-
ease status, we hypothesized that the association between high ferritin levels and all-cause mor-
tality in the general male population may be obscured by comorbidities. Other population
studies have provided weak evidence of such association among people without medical his-
tory of chronic diseases [23]. Further research on the prognostic role of ferritin amongst
healthy men is required.
In men, most studies have shown either positive or no relationship between circulating fer-
ritin and cardiovascular mortality independent of other causative factors [24,25]. Conversely, a
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Table 1. Baseline characteristics of men and women aged 50 years and over by ferritin level.
MEN (n = 2509) WOMEN (n = 2954)
Ferritin quartile Ferritin quartile
Model Lowest Second
lowest
Second
highest
Highest Lowest Second
lowest
Second
highest
Highest
2-69ng/
ml
70-118ng/
ml
119-193ng/
ml
194-
598ng/ml
p-value 2-44ng/
ml
45-73ng/ml 74-115ng/
ml
116-
341ng/ml
p-value
No. of participants 640 604 638 627 737 735 740 742
Mean (SD) age (years) <0.001 0.009
67.2
(9.9)
65.3 (8.9) 65.5 (9.0) 65.0 (8.8) 66.4
(10.5)
65.9 (9.7) 65.4 (9.4) 67.1 (9.1)
Marital status (%) 0.42 0.13
Married 477
(74.5)
472 (78.2) 486 (76.2) 487 (77.7) 421
(57.1)
452 (61.5) 449 (60.7) 467 (62.9)
Other 163
(25.5)
132 (21.9) 152 (23.8) 140 (22.3) 316
(42.9)
283 (38.5) 291 (39.3) 275 (37.1)
Smoking (%) 0.53 0.25
Current smoker 80 (12.5) 95 (15.7) 88 (13.8) 98 (15.6) 86 (11.7) 111 (15.1) 118 (15.9) 90 (12.1)
Former smoker 370
(57.8)
341 (56.5) 380 (59.6) 357 (57.0) 300
(40.7)
294 (40.0) 299 (40.4) 333 (44.9)
Never smoker 190
(29.7)
168 (27.8) 170 (26.6) 172 (27.4) 351
(47.6)
330 (44.9) 323 (43.7) 319 (43.0)
Physical activity (%) 0.022 0.065
Vigorous physical activity at
least once a week
193
(30.2)
226 (37.4) 222 (34.8) 218 (34.8) 186
(25.2)
204 (27.7) 208 (28.1) 176 (23.7)
Moderate physical activity at
least once a week
316
(49.4)
287 (47.5) 318 (49.8) 294 (46.9) 385
(52.2)
349 (47.5) 390 (52.7) 379 (51.1)
Mild physical activity at least
once a week
76 (11.9) 57 (9.4) 60 (9.4) 68 (10.8) 128
(17.4)
133 (18.1) 112 (15.1) 140 (18.9)
No physical activity at least
once a week
55 (8.6) 34 (5.6) 38 (6.0) 47 (7.5) 38 (5.2) 49 (6.7) 30 (4.1) 47 (6.3)
Body mass index (%) <0.001c <0.001c
<25kg/m2 188
(29.4)
169 (28.0) 121 (18.9) 115 (18.3) 258
(35.1)
220 (29.9) 234 (31.6) 174 (23.5)
25 to <30 kg/m2 296
(46.3)
290 (48.0) 331 (51.9) 279 (44.5) 254
(34.4)
293 (39.8) 277 (37.4) 277 (37.3)
 30 kg/m2 126
(19.7)
125 (20.7) 162 (25.4) 201 (32.1) 192
(26.1)
192 (26.2) 202 (27.3) 247 (33.3)
Missing 30 (4.7) 20 (3.3) 24 (3.8) 32 (5.1) 33 (4.5) 30 (4.1) 27 (3.7) 44 (5.9)
Education (%) 0.036 0.042
A-level or higher 228
(35.6)
245 (40.6) 287 (45.0) 248 (39.5) 177
(24.0)
217 (29.5) 202 (27.3) 169 (22.8)
GCSE/O-level/other
qualification
193
(30.2)
179 (29.6) 163 (25.5) 193 (30.8) 241
(32.7)
247 (33.6) 228 (30.8) 272 (36.7)
No qualifications 219
(34.2)
180 (29.8) 188 (29.5) 186 (29.7) 319
(43.3)
271 (36.9) 310 (41.9) 301 (40.6)
Wealth 0.003 0.001
Highest tertile (%) 181
(28.3)
216 (35.8) 242 (37.9) 240 (38.3) 205
(27.8)
229 (31.2) 262 (35.4) 248 (33.4)
Middle tertile (%) 235
(36.7)
213 (35.3) 210 (32.9) 196 (31.3) 233
(31.6)
251 (34.1) 248 (33.5) 246 (33.2)
Lowest tertile (%) 224
(35.0)
175 (29.0) 186 (29.2) 191 (30.5) 299
(40.6)
255 (34.7) 230 (31.1) 248 (33.4)
(Continued )
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single study has documented low ferritin in 196 patients with a first non-ST elevation acute
coronary syndrome and high mortality risk [26]. To our knowledge, this is the first study dem-
onstrating a significant relationship between high ferritin levels and cardiovascular mortality
in relatively healthy men with no major chronic diseases. However, the addition of the full
range of potential confounding factors, as well as markers of inflammation and lifestyle (like
smoking, physical activity and obesity) blunted this association in the male group, indicating
their higher influence over other factors. Nevertheless, the overall interaction between ferritin
levels and cardiovascular mortality seems to be more complex. Men without pre-existent
chronic diseases and high ferritin levels (194-598ng/ml) appeared with increased cardiovascu-
lar death risk independent of confounders. This has a clinical implication, since measured
Table 1. (Continued)
MEN (n = 2509) WOMEN (n = 2954)
Ferritin quartile Ferritin quartile
Model Lowest Second
lowest
Second
highest
Highest Lowest Second
lowest
Second
highest
Highest
2-69ng/
ml
70-118ng/
ml
119-193ng/
ml
194-
598ng/ml
p-value 2-44ng/
ml
45-73ng/ml 74-115ng/
ml
116-
341ng/ml
p-value
Anaemiaa (WHO
classification?)
<0.001 <0.001
Anaemic 76 (11.9) 14 (2.3) 21 (3.3) 25 (4.0) 97 (13.2) 22 (3.0) 28 (3.8) 26 (3.5)
Non-anaemic 564
(88.1)
590 (97.7) 617 (96.7) 602 (96.0) 640
(86.8)
713 (97.0) 712 (96.2) 716 (96.5)
Mean (SD) hsCRPb mg/L 0.003 <0.001
3.8 (6.8) 3.2 (5.3) 4.2 (7.7) 5.1 (13.8) 3.5 (6.0) 3.5 (5.2) 4.1 (7.1) 5.3 (12.0)
Mean (SD) fibrinogen g/L 0.64 0.073
3.2 (0.8) 3.2 (0.7) 3.2 (0.8) 3.1 (0.8) 3.3 (0.7) 3.3 (0.7) 3.3 (0.7) 3.3 (0.8)
Heart disease 0.54 0.31
Yes 51 (8.0) 60 (9.9) 51 (8.0) 51 (8.1) 34 (4.6) 28 (3.8) 22 (3.0) 23 (3.1)
No 589
(92.0)
544 (90.1) 587 (92.0) 576 (91.9) 703
(95.4)
707 (96.2) 718 (97.0) 719 (96.9)
Stroke 0.43 0.20
Yes 31 (4.8) 26 (4.3) 20 (3.1) 23 (3.7) 32 (4.3) 28 (3.8) 20 (2.7) 20 (2.7)
No 609
(95.2)
578 (95.7) 618 (96.9) 604 (96.3) 705
(95.7)
707 (96.2) 720 (97.3) 722 (97.3)
Cancer 0.76 0.95
Yes 41 (6.4) 35 (5.8) 40 (6.3) 32 (5.1) 57 (7.7) 58 (7.9) 61 (8.2) 63 (8.5)
No 599
(93.6)
569 (94.2) 598 (93.7) 595 (94.9) 680
(92.3)
677 (92.1) 679 (91.8) 679 (91.5)
Chronic lung disease 0.028 0.45
Yes 63 (9.8) 42 (7.0) 35 (5.5) 49 (7.8) 48 (6.5) 58 (7.9) 43 (5.8) 49 (6.6)
No 577
(90.2)
562 (93.0) 603 (94.5) 578 (92.2) 688
(93.5)
677 (92.1) 697 (94.2) 693 (93.4)
Diabetes Mellitus 0.009 0.095
Yes 72 (11.3) 44 (7.3) 44 (6.9) 67 (10.7) 55 (7.5) 46 (6.3) 51 (4.5) 23 (6.9)
No 568
(88.7)
560 (92.7) 594 (93.1) 560 (89.3) 682
(92.5)
689 (93.7) 707 (95.5) 691 (93.1)
aDefined according to the WHO classification of anaemia; In men, haemoglobin concentration <13g/dL, and in women, <12g/dL.
bHigh sensitivity C-reactive protein.
cThe missing category was not used in the estimation of p-values.
https://doi.org/10.1371/journal.pone.0178994.t001
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Table 2. Association between ferritin and all-cause and cardiovascular mortality by sex.
Model MEN WOMEN
Ferritin quartile Ferritin quartile
Lowest Second
lowest
Second
highest
Highest Lowest Second
lowest
Second
highest
Highest
2-69ng/ml 70-118ng/ml 119-193ng/ml 194-598ng/
ml
2-44ng/ml 45-73ng/ml 74-115ng/ml 116-341ng/
ml
All-cause mortality
No. of participants 640 604 638 627 737 735 740 742
No. of deaths 140 106 100 111 122 82 75 100
Person years of follow-up 4718 4582 4869 4732 5619 5756 5824 5758
Model 1 HR (95% CI)a 1.19 (0.92–
1.53)
1.16 (0.88–
1.53)
1.00
(reference)
1.16 (0.89–
1.52)
1.55 (1.16–
2.07)
1.05 (0.77–
1.43)
1.00
(reference)
1.22 (0.90–
1.65)
Model 2 HR (95% CI)b 1.07 (0.83–
1.39)
1.11 (0.84–
1.45)
1.00
(reference)
1.12 (0.86–
1.48)
1.46 (1.10–
1.96)
1.05 (0.77–
1.44)
1.00
(reference)
1.26 (0.93–
1.70)
Model 3 HR (95% CI)c 1.01 (0.78–
1.32)
1.13 (0.86–
1.49)
1.00
(reference)
1.12 (0.85–
1.47)
1.44 (1.08–
1.93)
1.06 (0.77–
1.45)
1.00
(reference)
1.26 (0.93–
1.70)
Model 4 HR (95% CI)d 1.04 (0.80–
1.36)
1.17 (0.89–
1.53)
1.00
(reference)
1.10 (0.84–
1.45)
1.56 (1.17–
2.09)
1.10 (0.80–
1.50)
1.00
(reference)
1.25 (0.92–
1.69)
Model 5 HR (95% CI)e 0.98 (0.75–
1.27)
1.16 (0.88–
1.53)
1.00
(reference)
1.07 (0.81–
1.41)
1.59 (1.18–
2.13)
1.11 (0.80–
1.52)
1.00
(reference)
1.23 (0.91–
1.66)
Excluding participants with
chronic diseasesf
No. of participants 433 432 485 446 557 553 580 570
No. of deaths 62 50 54 67 64 51 48 57
Person years of follow-up 3359 3378 3788 3427 4350 4371 4600 4499
Model 1 HR (95% CI)a 1.13 (0.79–
1.63)
1.16 (0.79–
1.70)
1.00
(reference)
1.52 (1.06–
2.18)
1.43 (0.99–
2.10)
1.12 (0.75–
1.65)
1.00
(reference)
1.12 (0.76–
1.64)
Model 2 HR (95% CI)g 1.04 (0.72–
1.50)
1.09 (0.74–
1.60)
1.00
(reference)
1.54 (1.08–
2.21)
1.42 (0.98–
2.07)
1.15 (0.78–
1.71)
1.00
(reference)
1.19 (0.80–
1.75)
Model 3 HR (95% CI)c 0.98 (0.67–
1.42)
1.10 (0.75–
1.62)
1.00
(reference)
1.56 (1.09–
2.24)
1.42 (0.97–
2.07)
1.15 (0.78–
1.71)
1.00
(reference)
1.18 (0.80–
1.74)
Model 4 HR (95% CI)d 1.05 (0.72–
1.53)
1.16 (0.79–
1.71)
1.00
(reference)
1.60 (1.12–
2.30)
1.50 (1.03–
2.19)
1.15 (0.77–
1.71)
1.00
(reference)
1.16 (0.79–
1.71)
Model 5 HR (95% CI)e 1.07 (0.73–
1.57)
1.16 (0.79–
1.72)
1.00
(reference)
1.49 (1.03–
2.16)
1.58 (1.08–
2.31)
1.11 (0.75–
1.66)
1.00
(reference)
1.12 (0.76–
1.66)
Cardiovascular mortality
No. of participants 640 604 638 627 737 735 740 742
No. of deaths 40 31 21 36 42 30 27 33
Person years of follow-up 4718 4582 4869 4732 5619 5756 5824 5758
Model 1 HR (95% CI)a 1.53 (0.90–
2.60)
1.62 (0.93–
2.81)
1.00
(reference)
1.77 (1.03–
3.04)
1.47 (0.90–
2.38)
1.07 (0.64–
1.80)
1.00
(reference)
1.14 (0.68–
1.89)
Model 2 HR (95% CI)b 1.41 (0.82–
2.40)
1.50 (0.86–
2.61)
1.00
(reference)
1.79 (1.04–
3.07)
1.43 (0.88–
2.33)
1.12 (0.66–
1.89)
1.00
(reference)
1.19 (0.71–
1.98)
Model 3 HR (95% CI)c 1.27 (0.74–
2.18)
1.62 (0.93–
2.83)
1.00
(reference)
1.77 (1.03–
3.04)
1.45 (0.89–
2.37)
1.11 (0.65–
1.88)
1.00
(reference)
1.18 (0.71–
1.98)
Model 4 HR (95% CI)d 1.35 (0.78–
2.31)
1.66 (0.95–
2.90)
1.00
(reference)
1.67 (0.97–
2.89)
1.60 (0.98–
2.62)
1.15 (0.68–
1.95)
1.00
(reference)
1.19 (0.71–
2.00)
Model 5 HR (95% CI)e 1.28 (0.74–
2.21)
1.77 (1.01–
3.11)
1.00
(reference)
1.62 (0.93–
2.82)
1.57 (0.95–
2.57)
1.09 (0.64–
1.86)
1.00
(reference)
1.11 (0.65–
1.87)
Excluding participants with
chronic diseasesf
No. of participants 433 432 485 446 557 553 580 570
No. of deaths 17 13 12 18 21 17 17 22
(Continued )
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ferritin levels higher from reference spectrum may add significant value in cardiovascular
prognosis in otherwise healthy men. A mechanistic explanation of all the aforementioned
interactions cannot be provided in the framework of an observational study. A recent, large,
general population survey demonstrated a U-shaped relationship of another marker of iron
status—transferrin saturation ratio (serum iron/total iron binding capacity)—with cardiovas-
cular mortality [27].
Evidence on the association between ferritin and mortality in women is limited. A recent
study of a general population sample indicated increased ferritin concentrations (>200ng/ml)
as an independent predictor of premature death, with the association following a linear rela-
tionship [27]. Other studies reported a U-shaped association among women, between ferritin
and cardiovascular mortality [14] and morbidity [28]. In our study, women in the lowest quar-
tile of ferritin levels had higher all-cause and cardiovascular mortality risk compared to those
in the reference quartile, albeit the latter did not reach significance. These associations
remained unchanged after adjustment for covariates including anemia and inflammatory
markers. Subgroup analysis also confirmed poor prognosis in women with low serum ferritin
in the absence of baseline chronic diseases. It should be noted that women in the lower ferritin
quartile do not necessarily suffer from iron stores depletion using the WHO definition [29].
Thus, our female population with otherwise “low normal” iron store and without anemia had
an elevated risk for premature death, which is of clinical importance.
Table 2. (Continued)
Model MEN WOMEN
Ferritin quartile Ferritin quartile
Lowest Second
lowest
Second
highest
Highest Lowest Second
lowest
Second
highest
Highest
2-69ng/ml 70-118ng/ml 119-193ng/ml 194-598ng/
ml
2-44ng/ml 45-73ng/ml 74-115ng/ml 116-341ng/
ml
Person years of follow-up 3359 3378 3788 3427 4350 4371 4600 4499
Model 1 HR (95% CI)a 1.32 (0.63–
2.76)
1.39 (0.64–
3.06)
1.00
(reference)
1.83 (0.88–
3.80)
1.36 (0.72–
2.58)
1.08 (0.55–
2.12)
1.00
(reference)
1.27 (0.67–
2.40)
Model 2 HR (95% CI)g 1.07 (0.51–
2.26)
1.17 (0.53–
2.58)
1.00
(reference)
2.00 (0.96–
4.17)
1.41 (0.74–
2.69)
1.12 (0.57–
2.20)
1.00
(reference)
1.37 (0.72–
2.61)
Model 3 HR (95% CI)c 0.97 (0.46–
2.08)
1.27 (0.57–
2.82)
1.00
(reference)
2.15 (1.02–
4.50)
1.41 (0.74–
2.70)
1.10 (0.56–
2.17)
1.00
(reference)
1.37 (0.72–
2.61)
Model 4 HR (95% CI)d 1.11 (0.52–
2.38)
1.38 (0.62–
3.08)
1.00
(reference)
2.23 (1.06–
4.69)
1.52 (0.79–
2.91)
1.09 (0.55–
2.15)
1.00
(reference)
1.35 (0.71–
2.58)
Model 5 HR (95% CI)e 1.23 (0.56–
2.70)
1.56 (0.69–
3.51)
1.00
(reference)
2.24 (1.03–
4.87)
1.55 (0.80–
2.98)
0.97 (0.48–
1.93)
1.00
(reference)
1.20 (0.62–
2.30)
HR = Hazard ratio; CI = Confidence interval; Significant results in bold
aAdjusted for age.
bAs model 1, plus adjustment for marital status, education, wealth, and baseline self-reported doctor diagnosed diseases i.e. heart disease, stroke, cancer,
chronic lung disease, and diabetes mellitus.
cAs model 2, plus adjustment for anaemia defined according to the WHO classification of anaemia; In men, haemoglobin concentration <13g/dL, and in
women, <12g/dL.
dAs model 3, plus adjustment for log high sensitivity C-reactive protein and fibrinogen.
eAs model 4, plus adjustment for smoking, physical activity and body mass index.
f Self-reported doctor diagnosis of heart disease, stroke, cancer, chronic lung disease, and diabetes mellitus.
gAs model 1, plus adjustment for marital status, education, and wealth.
https://doi.org/10.1371/journal.pone.0178994.t002
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The mechanism underlying the sex-specific associations between circulating ferritin and
mortality is likely to be complex, and may not simply reflect changes in body iron stores with
apparent clinical consequences [4]. For this reason, we excluded patients with excessive hyper-
ferritinemia indicating hemochromatosis, while anemia entered our adjustment models to
ascertain that it is not iron deficiency that drives the results. The most important finding of
this study was the sex-related relationship between ferritin and mortality. Although sex differ-
ences in the distribution of ferritin levels have previously been reported [30], it is still unknown
which iron-dependent or iron-independent mechanisms differentiate the association between
ferritin and mortality in men and women. Presumably, males and females respond differently
to iron-induced myocardial injury, as this has been implicated in an experimental study [31].
In parallel, elevated ferritin concentrations in men have been significantly related to higher
risk of metabolic diseases (for instance, hyperlipidemia, obesity, and diabetes) with consequent
increase of cardiovascular risk [16]. Notably, those relationships were not confirmed among
women. This gives rise to the assumption of sex-dependent differences in the expression of
regulatory molecules involved in iron metabolism or the non-iron related processes of ferritin
[32]. Nevertheless, the explanation of this sex-dependent behavior of ferritin is an unwieldy
process. Moreover, applying sex-specific normal range of ferritin concentrations may be con-
sidered for clinical decisions in the future.
Besides this, inflammatory processes may influence circulating ferritin levels. In the context
of cardiovascular disease, ferritin may exert a dual pro-inflammatory role. Its increased levels
may represent an acute phase reactant equivalently to hsCRP [33], while the reduced concen-
tration may also precipitate inflammation [34]. In summary, both high and low ferritin levels
may relate to enhanced inflammation, inducing the progression of cardiovascular and other
chronic diseases. In comparison to previous studies, the strength of our analysis was that it
took into consideration the impact of inflammation on ferritin levels. After adjustment for
well-established and sensitive markers of inflammation (CRP and fibrinogen), results
remained unaffected, which may outline the multi-functional role of ferritin, potentially
involved in other non-inflammatory pathways (e.g. angiogenesis or proliferation).
The present work has some limitations. First, our data lacked information on the use of
medication which is necessary for a mechanistic interpretation of the observed associations;
this might in part explain the observed variation of the association between ferritin and all-
cause mortality in men by chronic disease. Second, although we carried out sensitivity analyses
to limit the potential confounding effect of major chronic diseases, we cannot ignore the possi-
bility of unaccounted confounders having influenced our results. Third, in the absence of
widely accepted and validated ferritin cut-off points, we used sex-specific quartiles as an
acceptable and unbiased alternative categorization. However, their clinical relevance and
discriminatory power in the general population or groups with certain diseases remains
unknown. In parallel, all blood samples were momentarily measured at baseline and may have
been affected by transient factors. Although this is a common research practice we cannot rule
out the impact of unknown factors on the association between a single, snapshot measure-
ment, and long-term mortality. Lastly, the observational design of our study precludes any
causal inferences and therefore our findings should be interpreted with caution.
In conclusion, circulating ferritin levels showed sex-specific prognostic patterns in a com-
munity-based cohort. The risks of all-cause and cardiovascular mortality were increased
among healthy men with hyperferritinemia. Considering the whole male population, the high-
est ferritin quartile showed an association to cardiovascular mortality, but this association was
blunted after adjustment for inflammation and lifestyle covariates. Women with low serum
ferritin levels appeared to have higher all-cause mortality risk after adjustment for numerous
covariates. Therefore, ferritin levels may not only reflect iron store status, but also be of
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paramount importance in risk stratification of community-dwellers, tailoring pre-emptive
therapy. The rapid, sensitive, validated and low-cost blood assay makes ferritin a feasible and
widely used biomarker, and its potential implications for public health warrant further
investigation.
Supporting information
S1 Table. The associations between ferritin and mortality after excluding participants who
died within the first 24 months since the baseline interview, and participants with anaemia
or increased of hsCRP levels.
(DOCX)
Author Contributions
Conceptualization: NK PD.
Data curation: JB SR PD.
Formal analysis: JB SR PD.
Investigation: JB SR PD.
Methodology: JB SR MT PN PD.
Project administration: PD.
Resources: JB SR PD.
Supervision: PN PD.
Validation: JB SR PD.
Visualization: NK MT PD.
Writing – original draft: NK PN PD.
Writing – review & editing: NK JB SR MT PN PD.
References
1. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron
metabolism. Cell. 2004; 117:285–297. PMID: 15109490
2. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, et al; Japanese National
Research Group on Idiopathic Bone Marrow Failure Syndromes. Retrospective nationwide survey of
Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact
of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78:487–94. https://doi.org/10.1111/j.
1600-0609.2007.00842.x PMID: 17391310
3. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, et al. Iron deficiency ane-
mia—bridging the knowledge and practice gap. Transfus Med Rev. 2014; 28:156–66. PMID: 24931617
4. Oliveira F, Rocha S, Fernandes R. Iron metabolism: from health to disease. J Clin Lab Anal. 2014;
28:210–8. https://doi.org/10.1002/jcla.21668 PMID: 24478115
5. Watt RK. The many faces of the octahedral ferritin protein. Biometals. 2011; 24:489–500. https://doi.
org/10.1007/s10534-011-9415-8 PMID: 21267633
6. Tran TN, Eubanks SK, Schaffer KJ, Zhou CYJ, Linder MC. Secretion of ferritin by rat hepatoma cells
and its regulation by inflammatory cytokines and iron. Blood 1997; 90:4979–4986. PMID: 9389717
7. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009;
23:95–104. https://doi.org/10.1016/j.blre.2008.08.001 PMID: 18835072
8. Ji M, Li XD, Shi HB, et al. Clinical significance of serum ferritin in elderly patients with primary lung carci-
noma. Tumour Biol. 2014; 35:10195–9. https://doi.org/10.1007/s13277-014-2317-y PMID: 25027402
Association between ferritin and mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0178994 June 7, 2017 11 / 13
9. Mainous AG 3rd, Tanner RJ, Coates TD, Baker R. Prediabetes, elevated iron and all-cause mortality: a
cohort study. BMJ Open. 2014; 4:e006491. https://doi.org/10.1136/bmjopen-2014-006491 PMID:
25500370
10. Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated
with risk of coronary heart disease in women. J Nutr. 2008; 138:2436–41. https://doi.org/10.3945/jn.
108.097766 PMID: 19022969
11. Grammer TB, Kleber ME, Silbernagel G, Pilz S, Scharnagl H, Tomaschitz A, et al. Hemoglobin, iron
metabolism and angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular
Health Study). Atherosclerosis. 2014; 236:292–300. https://doi.org/10.1016/j.atherosclerosis.2014.07.
002 PMID: 25112800
12. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk—a systematic review and meta-analysis
of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev. 2014; 23:12–31. https://doi.org/
10.1158/1055-9965.EPI-13-0733 PMID: 24243555
13. Menke A, Muntner P, Ferna´ndez-Real JM, Guallar E. The association of biomarkers of iron status with
mortality in US adults. Nutr Metab Cardiovasc Dis. 2012; 22:734–40. https://doi.org/10.1016/j.numecd.
2010.11.011 PMID: 21330119
14. Sempos CT, Looker AC, Gillum RE, Mcgee DL, Vuong CV, Johnson CL. Serum ferritin and death from
all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition
Examination Study. Ann Epidemiol 2000; 10:441–8. PMID: 11023623
15. Marniemi J, Jarvisalo J, Toikka T, Raiha I, Ahotupa M, Sourander L. Blood vitamins, mineral elements
and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly
population. Int J Epidemiol 1998; 27:807.
16. Han LL, Wang YX, Li J, Zhang XL, Bian C, Wang H, et al. Gender differences in associations of serum
ferritin and diabetes, metabolic syndrome, and obesity in the China Health and Nutrition Survey. Mol
Nutr Food Res. 2014; 58:2189–95. https://doi.org/10.1002/mnfr.201400088 PMID: 25163435
17. Rushton DH, Barth JH. What is the evidence for gender differences in ferritin and haemoglobin? Crit
Rev Oncol Hematol. 2010; 73:1–9. https://doi.org/10.1016/j.critrevonc.2009.03.010 PMID: 19394859
18. Mindell J, Biddulph JP, Hirani V, Stamatakis E, Craig R, Nunn S, et al. Cohort profile: the health survey
for England. Int J Epidemiol. 2012; 41:1585–93. https://doi.org/10.1093/ije/dyr199 PMID: 22253315
19. http://www.who.int/vmnis/indicators/hemoglobin.pdf
20. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival
and complications in patients with thalassemia major treated with transfusion and deferoxamine. Hae-
matologica. 2004; 89:1187–93. PMID: 15477202
21. Ponikowska B, Suchocki T, Paleczny B, Olesinska M, Powierza S, Borodulin-Nadzieja L, et al. Iron sta-
tus and survival in diabetic patients with coronary artery disease. Diabetes Care. 2013; 36:4147–56.
https://doi.org/10.2337/dc13-0528 PMID: 24130349
22. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for
patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22:538–43. https://doi.org/10.
1038/sj.leu.2405070 PMID: 18079733
23. Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mor-
tality by moderately and markedly increased ferritin concentrations: general population study and meta-
analysis. Clin Chem. 2014; 60:1419–28. https://doi.org/10.1373/clinchem.2014.229013 PMID:
25156997
24. Kim KS, Son HG, Hong NS, Lee DH. Associations of serum ferritin and transferrin % saturation with all-
cause, cancer, and cardiovascular disease mortality: Third National Health and Nutrition Examination
Survey follow-up study. J Prev Med Public Health. 2012; 45:196–203. https://doi.org/10.3961/jpmph.
2012.45.3.196 PMID: 22712047
25. Eftekhari MH, Mozaffari-Khosravi H, Shidfar F, Zamani A. Relation between body iron status and car-
diovascular risk factors in patients with cardiovascular disease. Int J Prev Med. 2013; 4:911–6. PMID:
24049617
26. Dominguez-Rodriguez A, Carrillo-Perez Tome M, Hernandez-Garcia C, Arroyo-Ucar E, Juarez-Prera
R, Blanco-Palacios G, et al. Serum ferritin and acute coronary syndrome: a strong prognostic factor? Int
J Cardiol. 2011; 152:129–30. https://doi.org/10.1016/j.ijcard.2011.07.052 PMID: 21856027
27. Stack AG, Mutwali AI, Nguyen HT, Cronin CJ, Casserly LF, Ferguson J. Transferrin saturation ratio and
risk of total and cardiovascular mortality in the general population. QJM. 2014; 107:623–33. https://doi.
org/10.1093/qjmed/hcu045 PMID: 24599805
28. Friedrich N, Milman N, Vo¨lzke H, Linneberg A, Jørgensen T. Is serum ferritin within the reference range
a risk predictor of cardiovascular disease? A population-based, long-term study comprising 2874 sub-
jects. Br J Nutr. 2009; 102:594–600. https://doi.org/10.1017/S000711450922085X PMID: 19203421
Association between ferritin and mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0178994 June 7, 2017 12 / 13
29. WHO. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations.
Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/
NMH/NHD/MNM/11.2). (http://www.who.int/vmnis/indicators/serum_ferritin.pdf
30. Milman N, Byg KE, Ovesen L. Iron status in Danes 1994. II: Prevalence of iron deficiency and iron over-
load in 1319 Danish women aged 40–70 years. Influence of blood donation, alcohol intake and iron sup-
plementation. Ann Hematol. 2000; 79:612–21. PMID: 11131920
31. Das SK, Patel VB, Basu R, Wang W, DesAulniers J, Kassiri Z, et al. Females are protected from iron-
overload cardiomyopathy independent of iron metabolism: key role of oxidative stress. J Am Heart
Assoc. 2017; 6: pii: e003456.
32. Thulluri S, Wu M, Blough ER, Manne ND, Litchfield AB, Wang B. Regulation of iron-related molecules in
the rat hippocampus: sex- and age-associated differences. Ann Clin Lab Sci. 2012; 42:145–51. PMID:
22585610
33. Sung KC, Kang JH, Shin HS. Relationship of cardiovascular risk factors and serum ferritin with C-reac-
tive Protein. Archives of Medical Research. 2007; 38:121–125. https://doi.org/10.1016/j.arcmed.2006.
08.008 PMID: 17174735
34. Fan Y, Wang J, Wei L, He B, Wang C, Wang B. Iron deficiency activates pro-inflammatory signaling in
macrophages and foam cells via the p38 MAPK-NF-κB pathway. Int J Cardiol. 2011; 152:49–55. https://
doi.org/10.1016/j.ijcard.2010.07.005 PMID: 20674992
Association between ferritin and mortality
PLOS ONE | https://doi.org/10.1371/journal.pone.0178994 June 7, 2017 13 / 13
